A joint research program on cardiovascular and anti-inflammatory drugs by the Weizmann Institute of Science at Rehovot, and Rachelle Laboratories of the United States, was announced here today by Dr. George Krsek, president of the Long Beach pharmaceutical company.
Dr. Krsek said the program will be directed toward helping to control heart ailments, which still rate as America’s No. 1 killer disease. The joint research project will be conducted under the direction of Prof. William Taub, head of the Pharmaceutical Laboratory of the Weizmann Institute of Science. Dr. Krsek revealed that experimental work now being conducted at Weizmann by Prof. Taub is aimed at the synthesis of new compounds of possible hypnotic, sedative, antipyretic, diuretic and anti-inflammatory properties.
Help ensure Jewish news remains accessible to all. Your donation to the Jewish Telegraphic Agency powers the trusted journalism that has connected Jewish communities worldwide for more than 100 years. With your help, JTA can continue to deliver vital news and insights. Donate today.
The Archive of the Jewish Telegraphic Agency includes articles published from 1923 to 2008. Archive stories reflect the journalistic standards and practices of the time they were published.
